Wedbush raised the firm’s price target on Ultragenyx to $48 from $47 and keeps a Neutral rating on the shares. The preannouncement provided by Ultragenyx in January took much of the suspense out of the Q4 financial results update, as all figures provided at the release were consistent, the analyst tells investors in a research note. The firm seeks a more attractive entry point before getting constructive on shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RARE:
- Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
- RARE Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2023 Financial Results and Corporate Update
- Ultragenyx announces data demonstrating treatment with UX111
- Ultragenyx Announces Data Demonstrating Treatment with UX111 Results in Significant Reduction in Heparan Sulfate Exposure in Cerebrospinal Fluid Correlated with Improved Long-term Cognitive Function in Patients with Sanfilippo Syndrome Type A (MPS IIIA)